Thomas Keane to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications Thomas Keane has written about Antineoplastic Agents, Hormonal.
Connection Strength
1.447
-
Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017 Jun; 18(6):41.
Score: 0.525
-
Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80.
Score: 0.276
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
Score: 0.154
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
Score: 0.147
-
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
Score: 0.107
-
Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8.
Score: 0.068
-
Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1):46-52.
Score: 0.066
-
[Reevaluation of MAB therapy and progress of endocrine therapy]. Gan To Kagaku Ryoho. 2005 May; 32(5):705-28.
Score: 0.057
-
Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002 Aug; 60(2):201-8.
Score: 0.047